v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Medtech
ApiFix Ltd
Common Stock
Common Stock
Medtech
Common Stock
ApiFix Ltd
Additional Paid-in Capital
Additional Paid-in Capital
Medtech
Additional Paid-in Capital
ApiFix Ltd
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2023 $ 377,025     $ 6     $ 580,287     $ (197,742) $ (5,526)
Beginning balance (in shares) at Dec. 31, 2023       23,378,408              
Increase (Decrease) in Stockholders' Equity                      
Net loss (7,805)                 (7,805)  
Other comprehensive loss (gain) (1,435)                   (1,435)
Restricted stock 2,799           2,799        
Restricted stock (in shares)       162,003              
Ending balance at Mar. 31, 2024 370,584     $ 6     583,086     (205,547) (6,961)
Ending balance (in shares) at Mar. 31, 2024       23,540,411              
Beginning balance at Dec. 31, 2023 377,025     $ 6     580,287     (197,742) (5,526)
Beginning balance (in shares) at Dec. 31, 2023       23,378,408              
Increase (Decrease) in Stockholders' Equity                      
Net loss (13,834)                    
Other comprehensive loss (gain) (4,698)                    
Ending balance at Jun. 30, 2024 371,293     $ 6     593,087     (211,576) (10,224)
Ending balance (in shares) at Jun. 30, 2024       24,216,738              
Beginning balance at Mar. 31, 2024 370,584     $ 6     583,086     (205,547) (6,961)
Beginning balance (in shares) at Mar. 31, 2024       23,540,411              
Increase (Decrease) in Stockholders' Equity                      
Net loss (6,029)                 (6,029)  
Other comprehensive loss (gain) (3,263)                   (3,263)
Restricted stock 2,939           2,939        
Restricted stock (in shares)       426,227              
Stock portion of anniversary payment/installment   $ 133 $ 6,929         $ 133 $ 6,929    
Stock portion of anniversary payment/installment (in shares)         4,288 245,812          
Ending balance at Jun. 30, 2024 371,293     $ 6     593,087     (211,576) (10,224)
Ending balance (in shares) at Jun. 30, 2024       24,216,738              
Beginning balance at Dec. 31, 2024 354,566     $ 6     600,897     (235,564) (10,773)
Beginning balance (in shares) at Dec. 31, 2024       24,217,508              
Increase (Decrease) in Stockholders' Equity                      
Net loss (10,659)                 (10,659)  
Other comprehensive loss (gain) (853)                   (853)
Restricted stock 3,859           3,859        
Restricted stock (in shares)       601,547              
Issuance of common stock 233           233        
Issuance of common stock (in shares)       8,922              
Ending balance at Mar. 31, 2025 347,146     $ 6     604,989     (246,223) (11,626)
Ending balance (in shares) at Mar. 31, 2025       24,827,977              
Beginning balance at Dec. 31, 2024 354,566     $ 6     600,897     (235,564) (10,773)
Beginning balance (in shares) at Dec. 31, 2024       24,217,508              
Increase (Decrease) in Stockholders' Equity                      
Net loss (17,772)                    
Other comprehensive loss (gain) 5,827                    
Ending balance at Jun. 30, 2025 355,514     $ 6     613,790     (253,336) (4,946)
Ending balance (in shares) at Jun. 30, 2025       25,072,502              
Beginning balance at Mar. 31, 2025 347,146     $ 6     604,989     (246,223) (11,626)
Beginning balance (in shares) at Mar. 31, 2025       24,827,977              
Increase (Decrease) in Stockholders' Equity                      
Net loss (7,113)                 (7,113)  
Other comprehensive loss (gain) 6,680                   6,680
Restricted stock 5,252           5,252        
Restricted stock (in shares)       178,552              
Issuance of common stock 1,261           1,261        
Issuance of common stock (in shares)       55,143              
Stock portion of anniversary payment/installment   226           226      
Stock portion of anniversary payment/installment (in shares)         10,830            
Capital contribution associated with reclassification of MedTech liability to equity   $ 2,062           $ 2,062      
Ending balance at Jun. 30, 2025 $ 355,514     $ 6     $ 613,790     $ (253,336) $ (4,946)
Ending balance (in shares) at Jun. 30, 2025       25,072,502